Adalyon Appoints Ulrik Zeuthen as CEO
Adalyon, a pioneering tech-bio firm utilizing its AI-powered speech biomarker platform to remodel scientific drug growth, at present introduced the appointment of Ulrik Zeuthen, as Chief Executive Officer (CEO). Ulrik is an skilled chief in driving digital transformation within the pharmaceutical trade by way of information integration and synthetic intelligence (AI). Adalyon’s proprietary speech-based digital biomarkers present actionable insights into cognitive and behavioural affected person outcomes, serving to optimise scientific analysis.
Ulrik brings intensive expertise from the pharmaceutical and information science sectors, having beforehand held Director degree positions at Novo Nordisk, working in Denmark and Japan, and as a knowledge strategist at Deloitte. He has been chargeable for the institution and execution of partnerships between Novo Nordisk and first technical companions, to drive the scaled and accelerated AI use case supply throughout the corporate. He holds a Masters of Science (MSc) in Economics from the University of Copenhagen, Denmark.
“I’m excited to affix Adalyon, to leverage the deep experience of the workforce and the corporate’s sturdy heritage in behavioural science and know-how R&D for actual impression. Adalyon’s proprietary methodology utilising trendy AI/ML capabilities in extremely regulated environments stands out as market shaping. We’re pioneering quantified behavioural analytics to modernize scientific analysis,” mentioned Ulrik Zeuthen, CEO of Adalyon. “I’m wanting ahead to showcasing the worth of our AI-powered Behavioural Intelligence Platform in delivering real-time behavioural and emotional insights for scientific trials and healthcare purposes. Specifically, our adaptable ‘patient-centric’ strategy is designed as a plug-and-play know-how, driving higher affected person stratification and retention in trials, and with the potential to establish advantages in extra indications, enabling product label extensions and early detection of remedy results. Our know-how has the potential so as to add great worth to pharmaceutical R&D programmes by bettering scientific trial outcomes and finally delivering more practical medicine and affected person outcomes.”
Founder of Adalyon, Katarina Cantell, will transition to the position of Chief Scientific Officer (CSO). Dr Cantell holds a PhD in data methods and has performed doctoral analysis at Stanford University on the intersection of behavioural sciences and know-how. She brings over 20 years of expertise in digital well being and strategic management, together with government roles at Aava Medical and TietoEvry along with her earlier profession stemming from Polar Electro, wearables and the evolution of HRV right into a digital biomarker.
Dr Katarina Cantell, CSO and Founder of Adalyon commented, “Ulrik’s experience in making use of AI/ML & analytics in life sciences collectively together with his entrepreneur background and progress mindset makes him ideally suited to steer Adalyon into its subsequent chapter as we search partnerships with pharmaceutical firms to assist them in optimising scientific trials and enabling larger insights right into a affected person’s drug response profiles. Adalyon’s proprietary speech-based digital biomarker know-how is designed to seize the true voice of the affected person, not simply what their blood checks could say. We may say that speech is the brand new blood, and we’re utilizing it to attempt for a digital revolution in scientific drug growth.”
The present approach of measuring behavioural phenomena and drug response indicators in scientific trials depends closely on questionnaires and invasive samples, which are sometimes episodic, inflexible, and burdensome for members. This contributes to dropout charges reaching 40-50% and in lots of instances additionally incomplete and biased information. Adalyon’s know-how goals to deal with this burden and information hole by offering a non-invasive, high-frequency sign that improves sensitivity, reduces noise, and accelerates go/no-go choices. By seamlessly integrating into the present course of, it allows sponsors to recruit and retain the precise members and have interaction and monitor them extra successfully to assist earlier detection of remedy responses and lift main outcomes.
The put up Adalyon Appoints Ulrik Zeuthen as CEO first appeared on AI-Tech Park.
